Administration of GnRH Antagonist to Oocyte Donation Recipients (GnRH-Ovodon)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00635258

Recruitment Status : Completed

First Posted : March 13, 2008

Last Update Posted : March 13, 2008

Sponsor:

Collaborator:

University of Valencia

Information provided by:

Centro Ginecologia y Obstetricia.

Study Description

Brief Summary:

This prospective and randomized study was performed to evaluate whether the replacement of GnRH agonist by a GnRH antagonist in oocyte donation recipients during endometrial preparation has any impact on pregnancy and implantation rates.

Condition or disease	Intervention/treatment
Pregnancy Embryo Implantation	Drug: triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) Drug: GnRH antagonist (Orgalutran®)

Detailed Description:

This was a prospective and randomized study undertaken between January 2004 and December 2007. One hundred patients with an indication for oocyte donation with functioning ovaries and IVF with or without intracytoplasmatic sperm injection (ICSI) were recruited for the study. After assignment to IVF or IVF/ICSI randomization was performed to 1 of the 2 treatment groups (GnRH agonist or GnRH antagonist during endometrial preparation in oocyte donation recipients) using a computed-generated randomization schedule assigned via numbered sealed envelopes.

In our program, we used excess oocytes from IVF that were voluntarily donated by patients after informed consent.

The indications for oocyte donation were reduced ovarian reserve (59%), recurrent IVF failures (21%), premature ovarian failure (16%), and genetic anomaly (4%).

This study was performed according to the declaration of Helsinki and the European Community note on Good Clinical Practice for trials on medical products in the European Community (CPMP Working Party on Efficacy of Medical Products, 1990). Furthermore, the local ethics committee approved the study protocol, and written informed consent was obtained from all patients.

Study Design

Layout table for study information

Study Type :	Observational
Actual Enrollment :	100 participants
Observational Model:	Case-Control
Time Perspective:	Prospective
Official Title:	Administration of GnRH Antagonist to Oocyte Donation Recipients During Endometrial Preparation.
Study Start Date :	January 2004
Actual Primary Completion Date :	December 2007
Actual Study Completion Date :	December 2007

Resource links provided by the National Library of Medicine

Drug Information available for: Triptorelin Triptorelin pamoate Ganirelix Ganirelix acetate

U.S. FDA Resources

Groups and Cohorts

Group/Cohort	Intervention/treatment
GnRH-ant Patients were treated with a GnRH antagonist (Orgalutran®; 0,25 mg/d, sc.) commencing on day 1 of the menstrual cycle and maintained until the day of donor's hCG administration.	Drug: GnRH antagonist (Orgalutran®) GnRH antagonist (Orgalutran®; 0,25 mg/d, sc.) commencing on day 1 of the menstrual cycle and maintained until the day of donor's hCG administration. Other Name: GnRH antagonist
GnRH-a GnRH long protocol using 0.1 mg/day triptorelin s.c (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) was started on day 21-24 of the preceding cycle for at least 14 days to produce an agonadal state. Furthermore, the triptorelin administration was maintained until the day of donor's hCG administration.	Drug: triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) 0.1 mg/day triptorelin s.c (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) was started on day 21-24 of the preceding cycle for at least 14 days to produce an agonadal state. Other Name: GnRH agonist

Outcome Measures

Primary Outcome Measures :

pregnancy and implantation rates [ Time Frame: "at 7 weeks" ]

Secondary Outcome Measures :

age of the recipients, body mass index, days undergoing oestrogen therapy [ Time Frame: "at 1 mounth" ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 34 Years (Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes
Sampling Method:	Probability Sample

Study Population

Patients with an indication for oocyte donation with functioning ovaries.

Criteria

Inclusion Criteria:

Age between 18-34 years
Body mass index between 19-30 kg/m2;
History of regular menstrual cycles, ranging from 25-35 days
No relevant systemic disease (all patients were screened for hepatitis B and C, human immunodeficiency viruses I and II, syphylis, and vaginal infection), genetic disease, severe endometriosis or pelvic inflamatory disease
No more than two previous IVF cycles; and
No previous IVF cycles with poor response (less than three oocytes in a previous IVF cycle) or severe ovarian hyperstimulation syndrome.

Exclusion Criteria:

Patients without inclusion criteria.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00635258

Locations

Layout table for location information

Spain
CEGIOB
Valencia, Spain, 46004

Sponsors and Collaborators

Centro Ginecologia y Obstetricia.

University of Valencia

Investigators

Layout table for investigator information

Principal Investigator:	Raga Francisco, M.D., Ph.D.	Centro Ginecologia y Obstetricia.

More Information

Publications:

Casañ EM, Raga F, Bonilla-Musoles F, Polan ML. Human oviductal gonadotropin-releasing hormone: possible implications in fertilization, early embryonic development, and implantation. J Clin Endocrinol Metab. 2000 Apr;85(4):1377-81.

Raga F, Casañ EM, Kruessel J, Wen Y, Bonilla-Musoles F, Polan ML. The role of gonadotropin-releasing hormone in murine preimplantation embryonic development. Endocrinology. 1999 Aug;140(8):3705-12.

Casañ EM, Raga F, Polan ML. GnRH mRNA and protein expression in human preimplantation embryos. Mol Hum Reprod. 1999 Mar;5(3):234-9.

Raga F, Casañ EM, Wen Y, Huang HY, Bonilla-Musoles F, Polan ML. Independent regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-3 in human endometrial stromal cells by gonadotropin-releasing hormone: implications in early human implantation. J Clin Endocrinol Metab. 1999 Feb;84(2):636-42.

Raga F, Casañ EM, Kruessel JS, Wen Y, Huang HY, Nezhat C, Polan ML. Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle. Biol Reprod. 1998 Sep;59(3):661-9.

Layout table for additonal information

Responsible Party:	Fernando Bonilla-Musoles, CEGIOB
ClinicalTrials.gov Identifier:	NCT00635258
Other Study ID Numbers:	GnRH-ant.Ovodon
First Posted:	March 13, 2008 Key Record Dates
Last Update Posted:	March 13, 2008
Last Verified:	March 2008

Keywords provided by Centro Ginecologia y Obstetricia.:


GnRH antagonist oocyte donation pregnancy implantation

Additional relevant MeSH terms:

Layout table for MeSH terms

Triptorelin Pamoate Ganirelix Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Luteolytic Agents Contraceptive Agents, Female	Contraceptive Agents Reproductive Control Agents Antineoplastic Agents, Hormonal Antineoplastic Agents Hormone Antagonists

To Top